Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome.

Phase

N/A

Condition

Heart Disease

Chest Pain

Cardiac Disease

Treatment

N/A

Clinical Study ID

NCT01109706

BRD/10/03-ZE

Ages > 18
All Genders

Study Summary

PCSK9 (Proprotein convertase subtilisin kexin type 9) plays a key role in LDL-cholesterol (LDLC) metabolism by inhibiting LDL receptor (LDLR) at post-transcriptional level. PCSK9 loss of function mutations are associated to decreased LDLC levels and a cardiovascular protection. In this context, the development of pharmacological inhibitors of PCSK9, in association with statins treatment, represents a major therapeutic issue for LDLC modulation. It was previously shown that PCSK9 plasmatic concentration correlated with plasmatic LDLC, TG and glucose concentrations. However, no data are available on predictive value of PCSK9 plasmatic level concerning coronary disease severity.

The main objective of this study is to determine whether plasmatic PCSK9 concentration is linked to coronary damage severity in patients with acute coronary syndrome.

Eligibility Criteria

Inclusion

Inclusion criteria:

more than 18 years old
Acute coronary syndrome (ST+ or ST-)
2 groups of patients: with statin, and without statin treatment

Exclusion

Exclusion criteria:

Patient who had cancer during the last 5 years or with cancer in progress
Patient with severe infection in progress
Hepatic failure (TP<50%)
Severe kidney failure
Patient unable to give his consent to the study

Study Design

February 13, 2011

July 16, 2015

Connect with a study center

Nantes University Hospital
Nantes, 44093
France
Site Not Available
Nantes University hospital
Nantes, 44000
France
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.